BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

SGLT2 inhibitors: PRAC recommendation to minimise the risk of diabetic ketoacidosis, especially in atypical cases

2016.02.15

Active substance: canagliflozin | dapagliflozin | empagliflozin

The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency has completed the European safety review on SGLT2 inhibitors and has issued recommendations to minimise the risk of diabetic ketoacidosis.

To the risk assessment procedure (available in German only)

Details on the procedure can be found on the website of the European Medicines Agency (EMA):

SGLT2 inhibitors